

**Table 1: Baseline characteristics of ciprofloxacin and levofloxacin groups regarding demographics, and laboratory data.**

Drug	Ciprofloxacin		Levofloxacin	
	(n=100)		(n=100)	
Demographics and Laboratory data	Diabetic (N=50)	Non-diabetic (N=50)	Diabetic (N=50)	Non-diabetic (N=50)
Age (Yr)	48.7±14.7	44±15	53.5±11.5	51.4±12.4
Gender (males/ females)	27/23	30/20	26/24	28/22
Height(cm)	165±5.8	166.6±6.1	165.5±5.6	165±7.5
Body weight(Kg)	73.4±9.6	71.2±11.6	73.9±12.7	71.5±11.7
Serum Na (mEq/L)	139.7±2.7	138.8±2.6	139±3.2	138±2.6
Serum K (mEq/L)	4.3±0.6	4.2±0.45	4.6±0.57	4.1±0.44
Serum Mg(mg/dL)	1.8±0.11	1.8±0.95	1.8±0.097	1.8±0.1
Liver function:				
ALT(U/L)	25.8±9	24.2±12	31.4±10	24.6±8.6
AST(U/L)	32±11	28.8±9	33.4±9	28.3±10

<b>Creatinine clearance(mL/min)</b>	107±43	99±39	90±26.6	93±32.9
-------------------------------------	--------	-------	---------	---------

- Data are presented as mean ± SD.

**Table 2: Comparison of QTc between each group regarding times.**

<b>Drug</b>	<b>Time DM Or Non</b>	<b>Baseline</b>	<b>24 hours after the 1<sup>st</sup> dose</b>	<b>72 hours after the 1<sup>st</sup> dose</b>	<b>72 hours after cessation.</b>
Ciprofloxacin	Diabetic	402±31.4	417±26.7*	416±26.4*	419.8±19.7*
	Non diabetic	404±52.6	417±32	428±31.9*	418.7±20.4*
Levofloxacin	Diabetic	414±29.5	427.4±38.3*	436±26*	425±21.7*
	Non diabetic	411±32.8	426±30.5*	434±35*	422±30.5*

- \*considered significant  $P < 0.05$  compared to baseline value.
- Data are presented as mean QTc (msec) ± SD.

**Table 3: Comparison between laboratories data before and after antibiotic administration.**

<b>Drug</b>	<b>Ciprofloxacin (n=100)</b>	<b>Levofloxacin (n=100)</b>
-------------	----------------------------------	---------------------------------

	Diabetic (n=50)		Non-diabetic (N=50)		Diabetic (N=50)		Non-diabetic (N=50)	
Laboratory data	before	after	before	after	before	after	before	after
Serum Na (mEq/L)	139.7±2.7	139±2	138.8±2.6	138.7±2.9	139±3.2	138±4*	138±3.3	138±2.4
Serum K (mEq/L)	4.3±0.6	4.2±0.5	4.2±0.45	4.3±0.5	4.6±0.57	4.1±0.4*	4.1±0.44	3.9±0.2*
Serum Mg(mg/dL)	1.8±0.11	1.9±0.1	1.8±0.95	1.8±0.1	1.8±0.097	1.8±0.08	1.82±0.1	1.79±0.07
Liver function:								
ALT(U/L)	25.8±9	27±10	24.2±12	26±11	31.4±10	38±6*	24.6±10	23.7±8
AST(U/L)	32±11	35.3±4*	28.8±9	33±5*	33.4±9	37.2±3*	28.3±10	25.8±9
Creatinine clearance(mL/min)	107±43	110±35	99±39	105±34	90±26.6	88±19	93±32.9	94.5±28

- \* considered significant  $P < 0.05$  compared to baseline value.
- Data are presented as mean ± SD.

**Table 4: Comparison between ciprofloxacin and levofloxacin regarding their risk on dysglycemia.**

Time	After 24 hours from 1 <sup>st</sup> dose		After 72 hours from 1 <sup>st</sup> dose		After 72 hours from antibiotics cessation.	
	Number of patients (%)		Number of patients (%)		Number of patients (%)	
Drug	ciprofloxacin	levofloxacin	ciprofloxacin	levofloxacin	Ciprofloxacin	levofloxacin
<b>All patient</b>	(n=100)	(n=100)	(n=100)	(n=100)	(n=100)	(n=100)
Hyperglycemia	21(21%)	38(38%)*	19(19%)	32(32%)*	7(7%)	11(11%)
Hypoglycemia	2(2%)	3(3%)	0(0%)	8(8%)*	0(0%)	0(0%)
<b>Diabetic Patients</b>	(n=50)	(n=50)	(n=50)	(n=50)	(n=50)	(n=50)
Hyperglycemia	5(10%)	10(20%)	2(4%)	10(20%)*	0(0%)	1(2%)
Hypoglycemia	1(2%)	0(0%)	0(0%)	1(2%)	0(0%)	0(0%)
<b>Non-diabetic patients</b>	(n=50)	(n=50)	(n=50)	(n=50)	(n=50)	(n=50)
Hyperglycemia	16(32%)	28(56%)*	17(34%)	22(44%)	7(14%)	10(20%)
Hypoglycemia	1(2%)	3(6%)	0(0%)	7(14%)*	0(0%)	0(0%)

\* Considered significant  $P < 0.05$  compared to ciprofloxacin group